Figure 1From: A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell diseaseAdaptive study design Phase A and Phase B. Decisions about dose allocations were made as the trial progressed. If interim analysis of pharmacodynamic data revealed insufficient platelet inhibition in the first 16 patients randomized to 5-mg daily prasugrel, the dose was to be escalated to 7.5 mg. Dotted line denotes dose escalation plan per protocol; no dose escalation occurred occur during the studyBack to article page